Ovoca Bio plc
OVB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 5.37 | 0.14 | -0.32 | -0.02 |
| FCF Yield | -0.28% | 136.75% | -115.90% | -32.35% |
| EV / EBITDA | 7,805.02 | 4.66 | -0.23 | -1.29 |
| Quality | ||||
| ROIC | -0.15% | -203.88% | -73.05% | -39.66% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.52 | -0.24 | 0.92 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -206.57% | 120.48% | -14.49% | -79.30% |
| Safety | ||||
| Net Debt / EBITDA | -49.14 | 6.08 | 1.08 | 1.14 |
| Interest Coverage | 0.00 | 0.00 | -143.00 | -253.81 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |